
Xena offers 3D Surgical Intelligence for gynecology, utilizing AI to detect conditions like Endometriosis, Adenomyosis, and Fibroids. Their platform provides precision 3D visualization for better surgical planning and outcomes, mapping disease extent, measuring structures accurately, and optimizing team and OR resources. Xena has demonstrated proven results with over 23 cases across 10 pilot institutions, achieving 91% disease mapping accuracy and 89% better OR planning, with a 94% surgeon satisfaction score. Their business model appears to involve providing a secure upload service for MRI scans, generating expert-validated 3D models within 48 hours, which are then accessed via a secure portal for planning and collaboration. The company emphasizes patient care by transforming consultations into clear visual experiences and is compliant with healthcare privacy standards like HIPAA, offering an FDA-exempt research tool for clinical pilots.

Xena offers 3D Surgical Intelligence for gynecology, utilizing AI to detect conditions like Endometriosis, Adenomyosis, and Fibroids. Their platform provides precision 3D visualization for better surgical planning and outcomes, mapping disease extent, measuring structures accurately, and optimizing team and OR resources. Xena has demonstrated proven results with over 23 cases across 10 pilot institutions, achieving 91% disease mapping accuracy and 89% better OR planning, with a 94% surgeon satisfaction score. Their business model appears to involve providing a secure upload service for MRI scans, generating expert-validated 3D models within 48 hours, which are then accessed via a secure portal for planning and collaboration. The company emphasizes patient care by transforming consultations into clear visual experiences and is compliant with healthcare privacy standards like HIPAA, offering an FDA-exempt research tool for clinical pilots.
What they do: AI-driven 3D surgical intelligence for gynecology (endometriosis, adenomyosis, fibroids)
HQ: Mannheim, Baden-Württemberg, Germany
Stage / funding: Pre-Seed (announced 2024-08-09); total funding reported USD 220,000
Team size: Approximately 2–10 employees (reported employee count 4)
Gynecologic surgical diagnostics and preoperative planning (soft-tissue disease mapping such as endometriosis, adenomyosis, fibroids).
Healthtech / Medtech
220000.00 USD
“Techstars participation”